Interferon production by individual L cells

Autologous and allogenic hybrid cell vaccine in patients with metastatic renal cell carcinoma

OBJECTIVE

To evaluate the safety, acute and long-term toxicity and therapeutic activity of an allogenic and an autologous hybrid cell vaccine in patients with progressive metastatic renal cell carcinoma (RCC).

PATIENTS AND METHODS

Eleven patients were vaccinated with a lethally irradiated hybrid cell vaccine of allogenic RCC tumour cells fused with major histocompatibility complex class I-matched and class II-unmatched activated allogenic lymphocytes. These patients were then followed for a mean of 11 months. Another 13 patients were vaccinated with a hybrid cell vaccine of autologous tumour cells fused with allogenic activated lymphocytes and followed for a mean of 6 months.

RESULTS

Six of the 11 patients receiving the allogenic vaccination showed an initial response, with two complete and two partial responses to date. Only three patients who received autologous vaccination responded to treatment.

CONCLUSIONS

Hybrid cell vaccination is a promising new approach in the treatment of patients with advanced RCC.

Postoperative active specific immunization in curatively resected colorectal cancer patients with a virus-modified autologous tumor cell vaccine

Active specific immunotherapy was performed in a phase I study in 20 colorectal cancer patients after surgical resection of the tumor. An autologous tumor cell vaccine surface modified by Newcastle disease virus (NDV) was used, which showed the following characteristics. After mechanical and enzymatic dissociation of the tumor tissue an average of 5 x 10(7) cells/g tissue was obtained. According to trypan blue dye exclusion assay the average viability was 72%. Following irradiation (200 Gy) the inactivation of proliferative activity of the cells could be demonstrated by the absence of incorporation of 3H-labelled thymidine. The cells were, however, still metabolically active as shown by the incorporation of [3H]-uridine and a mixture of 3H-labelled amino acids. Epithelium-specific antigens (detected by mAb HEA125) were expressed on more than 75% cells of the cell suspension indicating a high amount of (epithelium-derived) tumor cells. In order to increase the immunogenicity of the tumor cells the suspended cells were infected by the nonlytic, apathogenic Ulster strain of NDV. The successful modification of tumor cells with NDV could be shown by electron microscopy. Three weeks postoperatively cells were thawed, virus-modified, and inoculated intradermally in the upper thigh. Several cell and virus concentrations were tested in each patient. As control, tumor cells without NDV, NDV alone and normal colon mucosa were used. The number of tumor cells ranged from 2 x 10(6) up to 2 x 10(7) cells and NDV concentrations from 4 to 64 hemagglutination units (HU) were tested. Sixteen patients responded with a delayed-type hypersensitivity (DTH) skin reaction to the vaccine. The best DTH reaction, measured 24 h following vaccination, was obtained using a vaccine consisting of 1 x 10(7) tumor cells and 32 HU NDV (median induration of 8 mm). Response to NDV alone was seen in 2 patients only (median induration of 3 mm); 12 patients responded to tumor cells (1 x 10(7) alone (median induration of 4 mm). Of 10 patients tested with normal colorectal mucosa, 4 responded with a median induration of 3.5 mm. DTH responses to the vaccine of 1 x 10(7) tumor cells and 32 HU NDV increased throughout the repeated vaccinations to a median induration of 9.5 mm at the end of the therapy. No severe side-effects in the course of the immunotherapy, except for mild fever in 4/20 patients, were observed. The results of our phase I study show that this type of autologous colorectal tumor cell vaccine is ready for a large clinical trial to prove its efficacy.

Determination of human leukocyte populations involved in production of interferons alpha and gamma

Human mononuclear leukocyte populations separated into T-, B-, and monocyte-enriched fractions, were evaluated for their abilities to produce interferons when induced with either virus, double-stranded RNA or mitogens. The main producer of alpha-interferon was the B-cell enriched subpopulation, but these cells did not produce gamma-interferon. In contrast, the T-cell enriched population produced either alpha or gamma interferons, depending upon the type of inducer used. The monocyte-enriched population was also able to produce either alpha or gamma interferon. The presence of monocytes in T-cell enriched populations enhanced the levels of alpha interferon production, and removal of monocytes from T-cell enriched populations diminished levels of alpha interferon produced. Even though each of the mononuclear populations (B-, T-, and monocytes) were able to produce alpha-interferon in response to poly rI.polyrC, it was found, by using a single-cell production assay, that only about 0.1% of the total mononuclear population actually produced alpha-interferon when so induced. Similarly, using the single-cell production assay, it was demonstrated that gamma-interferon was produced by only a small proportion of induced T-cells (possibly on T-cell subpopulation), as only about 1 T-cell per 1,000 responded to PHA by production of gamma-interferon.